May,2023, Cholesgen (Shanghai) Co. Ltd. completed A round of financing worth over 100 million RMB. The round was led by Gaorong Capital, with participation from Great Filter Venture, Nanwan Baioao Investment Fund, and AstraZenec CICC venture capital. The angel investor, Trinity Innovation Fund (TIF), also participated in this round. The company will use the funds to accelerate the clinical development of its core innovative drug pipeline, expand its research and development team, and explore external collaborations and office research venues.
Cholesgen (Shanghai) Co. Ltd. was established in 2021 as a biopharmaceutical company dedicated to developing cholesterol metabolism innovative drugs. The company focuses on new disease targets and conducts innovative drug research and development for major diseases such as metabolic diseases (hyperlipidemia, obesity, diabetes, atherosclerosis, and NASH) and tumors based on biochemistry, disease biology, medicinal chemistry, and clinical translational medicine.
Cholesterol is an essential lipid substance for life activities. It is an important component of cell membranes, regulating membrane fluidity and phase transition. It is a precursor for the body to synthesize bile acids and steroid hormones, and participates in many important signal transduction pathways within cells. Abnormal cholesterol metabolism is closely related to hyperlipidemia, type 2 diabetes, non-alcoholic fatty liver disease, atherosclerotic cardiovascular disease, as well as neurodegenerative diseases and tumors. The founding team of Cholesgen (Shanghai) Co. Ltd. has been deeply involved in the field of cholesterol metabolism for more than 20 years. It is the only China new drug development company known to focus on cholesterol-related targets and regulatory methods, and its research and development pipeline consists of multiple innovative targets/mechanisms validated in human genetic studies. Cholesgen (Shanghai) Co. Ltd. http://www.cholesgen.com/news_info/id-6.html
|Cholesgen (Shanghai) Co. Ltd. http://www.cholesgen.com/news_info/id-6.html